Evidence map›Paper›PMID 37155629›Full record

Trial reportPloS one2023

Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial.

Rania Hammami, Omar Masmoudi, Jihen Jdidi, Mouna Turki, Rim Charfi, Imtinene Ben Mrad, Amine Bahloul, Tarek Ellouze, Rania Gargouri, Samir Kammoun and 3 more

Open access · goldFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Rania HammamiCardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.ORCID 0000-0003-1168-6450
Omar MasmoudiCardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.
Jihen JdidiEpidemiology Department, Hedi Chaker Hospital, University of Medicine, Sfax, Tunisia.
Mouna TurkiBiochemistry Department, Habib Bourguiba Hospital, University of Medicine, Sfax, Tunisia.
Rim CharfiBiochemistry Department, Habib Bourguiba Hospital, University of Medicine, Sfax, Tunisia.
Imtinene Ben MradCardiology Department Habib Thameur Hospital, Tunis, Tunisia.
Amine BahloulCardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.ORCID 0000-0003-1632-5646
Tarek EllouzeCardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.
Rania GargouriCardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.
Samir KammounCardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.
Selma CharfeddineCardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.
Fatma AyediBiochemistry Department, Habib Bourguiba Hospital, University of Medicine, Sfax, Tunisia.
Leila AbidCardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.
University of Sfax · TNHopital Universitaire Habib Bourguiba · TNHabib hospital Thameur · TNHopital Universitaire Hedi Chaker · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis trial aimed to assess the efficacy of Atorvastatin reloading on the prevention of Contrast-induced nephropathy (CIN) in patients pre-treated with this statin and undergoing coronary catheterization.

methodsThis was a prospective randomized controlled study including patients on chronic atorvastatin therapy. We randomly assigned the population to the Atorvastatin Reloading group (AR group), by reloading patients with 80 mg of atorvastatin one day before and three days after the coronary procedure, and the Non-Reloading group (NR group), including patients who received their usual dose without a reloading dose. The primary endpoints were the incidence of cystatin (Cys)-based CIN and Creatinine (Scr)-based CIN. The secondary endpoints consisted of the changes in renal biomarkers (Δ biomarkers) defined as the difference between the follow-up level and the baseline level.

resultsOur population was assigned to the AR group (n = 56 patients) and NR group (n = 54 patients). The baseline characteristics of the 2 groups were similar. Serum creatinine (SCr)-based CIN occurred in 11.1% in the NR group, and in 8.9% in the AR group without any significant difference. Cys-based CIN occurred in 37% in the NR group and 26.8% in the AR group without any significant difference. The subgroup analysis showed that high dose reloading had significantly reduced the CYC-based CIN risk in patients with type 2 diabetes (43.5% vs 18.8%, RR = 0.43. CI 95% [0.18-0.99])). The comparison of "Δ Cystatin" and Δ eGFR between the AR and NR groups didn't show any significant difference. However, cystatin C had significantly increased between baseline and at 24 hours in the NR group (0.96 vs 1.05, p = 0.001), but not in the AR group (0.94 vs 1.03, p = 0.206).

conclusionsOur study did not find a benefit of systematic atorvastatin reloading in patients on chronic atorvastatin therapy in preventing CIN. However, it suggested that this strategy could reduce the risk of CyC-based CIN in diabetic type 2 patients.

Indexed as

Diabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsKidney DiseasesPercutaneous Coronary InterventionAtorvastatinBiomarkersContrast MediaCoronary AngiographyCreatinineHumansProspective StudiesTreatment OutcomeAtorvastatinBiomarkersContrast MediaCreatinineHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID37155629
PMCPMC10166561
OpenAlexW4375955942

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.